ARCHIMEDES
Biodegradable Biliary and Pancreatic Stent

with three degradation profiles
Fast, Medium and Slow

The ARCHIMEDES Stent is a Biodegradable Biliary and Pancreatic Stent intended to be used to drain obstructed biliary or pancreatic ducts.1 The patented helical design of the stent allows for bile to flow on the outer extremity of the device while supporting the opening of the lumen.

Enhanced features

Different degradation profiles to cover a variety of malignant and benign underlying diseases.
Sinusoidal helical-channel design to allow bile to flow on the outside of the stent.
Mitigation of stent occlusion due to the degradation process of the stent materials.
Better simulated flow rates than tested plastic stent predicates.
Better simulated migration resistance than tested plastic stent predicates.
Equivalent crush resistance to tested plastic stent predicates.


DEGRADATION PROFILES
Stent Degradation Profiles* Minimal Strength Retention** Underlying diseases with
obstructed biliary duct
Underlying diseases with
obstructed pancreatic duct
FAST
degrading
stent
12 days
  • Cholelithiasis / Choledocholithiasis
  • Acute biliary pancreatitis
  • Cholangitis
  • Modified anatomy procedures involving biliary and pancreatic ducts such as liver transplants, Whipples and alike
  • Post ERCP pancreatitis
  • Acute pancreatitis
MEDIUM
degrading
stent
20 days
  • Cholelithiasis / Choledocholithiasis
  • Biliary leaks
  • Cystic duct leaks
  • Resectable CBD obstruction
  • Cholangitis
  • Modified anatomy procedures involving biliary and pancreatic ducts such as liver transplants, Whipples and alike
  • Pancreatic duct disruptions / leaks
SLOW
degrading
stent
11 weeks
  • Cholelithiasis / Choledocholithiasis
  • Benign biliary strictures
  • Malignant strictures
  • Biliary leaks
  • Cholangitis
  • Modified anatomy procedures involving biliary and pancreatic ducts such as liver transplants, Whipples and alike
  • Chronic pancreatitis
  • Pancreatic duct strictures

* The different degradation profiles are designed for obstructed biliary or pancreatic ducts with various underlying diseases.

** Minimal Strength Retention is defined by the presence of at least 10% of an initial strength parameter. The Stent remains intact with no breaks, tested in a simulated degradation model.

1 ARCHIMEDES BPS Instructions for Use (IFU ARCHIMEDES BPS_02 – 093A47_200505)

2 2019 Frost & Sullivan Independent Market Research Report.

The product official name is ARCHIMEDES BPS Pancreaticobiliary Stent.

For further inquiries regarding the ARCHIMEDES,
call +49 4171 6905 57-0 or email us at info@amggastro.com
BROCHURE